Balasubramanyam M, Mohan V
Madras Diabetes Research Foundation (MDRF), 35 Conran Smith Road, Gopalapuram, Chennai 600 086, India.
J Biosci. 2001 Sep;26(3):383-90. doi: 10.1007/BF02703748.
The war against diabetes through the development of new drugs is an ongoing continuous process to counter the alarming global increase in the prevalence of diabetes and its complications, particularly in developing countries like India. Unfortunately, the speed with which our knowledge of diabetes and its effects is expanding is not matched by the availability of new drugs. Following the identification of the insulin receptor (IR), its intrinsic kinase activity and molecular cloning, many studies have looked at IR as an ideal drug target. This review summarizes in brief the latest advancements in this field with particular reference to the current situation in respect of the development of orally active insulin mimetics in the treatment of type 2 diabetes.
通过研发新药对抗糖尿病的斗争是一个持续不断的过程，以应对全球糖尿病及其并发症患病率惊人增长的情况，尤其是在印度这样的发展中国家。不幸的是，我们对糖尿病及其影响的认知扩展速度与新药的可获得性并不匹配。在鉴定出胰岛素受体（IR）、其内在激酶活性及分子克隆之后，许多研究将IR视为理想的药物靶点。本综述简要总结了该领域的最新进展，特别提及了口服活性胰岛素模拟物治疗2型糖尿病的研发现状。
